Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MGTX Meiragtx Holdings Plc

Closed 11-06 16:00:00 EST

9.00

+0.49

+5.76%

盘后9.00

+0.000.00%

16:20 EST

High9.12	Low8.44	Vol703.33K
Open8.44	D1 Closing8.51	Amplitude7.99%
Mkt Cap864.39M	Tradable Cap483.15M	Total Shares96.04M
T/O6.29M	T/O Rate1.31%	Tradable Shares53.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MGTX","market":"US","secType":"STK","nameCN":"Meiragtx Holdings Plc","latestPrice":9,"timestamp":1793998800000,"preClose":8.51,"halted":0,"volume":703329,"hourTrading":{"tag":"盘后","latestPrice":9,"preClose":9,"latestTime":"16:20 EST","volume":5360,"amount":48240,"timestamp":1794000000895,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.05757931844888369,"floatShares":53683800,"shares":96043000,"eps":0.87,"marketStatus":"Closed","change":0.49,"latestTime":"11-06 16:00:00 EST","open":8.44,"high":9.12,"low":8.44,"amount":6286200,"amplitude":0.079906,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.87,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1528430400000,"exchange":"NASDAQ","adjPreClose":8.51,"preHourTrading":{"tag":"盘前","latestPrice":8.6,"preClose":8.51,"latestTime":"09:29 EST","volume":164,"amount":1409.053396,"timestamp":1793975399999,"change":0.09,"changeRate":0.010576,"amplitude":0.022327},"postHourTrading":{"tag":"盘后","latestPrice":9,"preClose":9,"latestTime":"16:20 EST","volume":5360,"amount":48240,"timestamp":1794000000895,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.297639,"impliedVol":2.3686,"impliedVolPercentile":0.9163},"requestUrl":"/m/hq/s/MGTX","defaultTab":"news","newsList":[{"id":"2678172940","title":"MeiraGTx Reports Preclinical Gene Therapy Data Showing Retinal Protection in Dry AMD Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2678172940","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678172940?lang=en_us&edition=fundamental","pubTime":"2026-10-27 20:09","pubTimestamp":1793102988,"startTime":"0","endTime":"0","summary":"MeiraGTx reports preclinical gene therapy data showing retinal protection in dry AMD modelsMeiraGTx will present four research posters at the ESGCT congress and NEALS annual meeting, both scheduled fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDL93Jy8y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","BK4112","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","MGTX","IE00BQXX3F31.USD","NDAQ","LU2095319765.USD","BCDF","BK4139","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678723231","title":"MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2678723231","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678723231?lang=en_us&edition=fundamental","pubTime":"2026-10-27 20:00","pubTimestamp":1793102400,"startTime":"0","endTime":"0","summary":"Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy PlatformsLONDONandNEW YORK, Oct.  27, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a verti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/27/3388913/0/en/meiragtx-announces-four-posters-at-the-european-society-of-gene-and-cell-therapy-esgct-2026-annual-congress-and-the-network-of-excellence-for-als-neals-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677170648","title":"MeiraGTx CFO and COO Richard Giroux Sells $557,200 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2677170648","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677170648?lang=en_us&edition=fundamental","pubTime":"2026-10-21 08:58","pubTimestamp":1792544282,"startTime":"0","endTime":"0","summary":"MeiraGTx CFO and COO Richard Giroux Sells $557,200 in Common SharesMeiraGTx CFO and COO Richard Giroux sold 56,000 ordinary shares on Oct. 20, 2026.The reported sale price was $9.95 per share, leaving","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL8jtQ44:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"MeiraGTx CFO and COO Richard Giroux Sells $557,200 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673061481","title":"MeiraGTx Chief Scientific Officer, Ophthalmology Stuart Naylor Sells 27,659 Shares for $294,291","url":"https://stock-news.laohu8.com/highlight/detail?id=2673061481","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673061481?lang=en_us&edition=fundamental","pubTime":"2026-10-07 08:54","pubTimestamp":1791334441,"startTime":"0","endTime":"0","summary":"MeiraGTx Chief Scientific Officer, Ophthalmology Stuart Naylor sells 27,659 shares for $294,291MeiraGTx: Chief Scientific Officer, Ophthalmology Stuart Naylor sold 27,659 ordinary shares on Oct. 6, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL5HzyRm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MeiraGTx Chief Scientific Officer, Ophthalmology Stuart Naylor Sells 27,659 Shares for $294,291","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670443666","title":"MeiraGTx: Promising Gene Therapy Platform but Early-Stage Risks Keep Risk/Reward Balanced at Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2670443666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670443666?lang=en_us&edition=fundamental","pubTime":"2026-09-25 14:35","pubTimestamp":1790318134,"startTime":"0","endTime":"0","summary":"Andrea Newkirk, an analyst from Goldman Sachs, has initiated a new Hold rating on Meiragtx Holdings (MGTX). Andrea Newkirk has given his Hold ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/meiragtx-promising-gene-therapy-platform-but-early-stage-risks-keep-risk-reward-balanced-at-hold-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/meiragtx-promising-gene-therapy-platform-but-early-stage-risks-keep-risk-reward-balanced-at-hold-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002270589.USD","LU2471134879.HKD","BK4139","IE00BFXG1179.USD","BK4585","LU2265009873.SGD","LU1791807156.HKD","LU0251131958.USD","LU0096364046.USD","LU0106831901.USD","BK4588","LU2750360997.AUD","BK4127","IE0004086264.USD","LU0345770308.USD","LU0942090050.USD","LU2237443978.SGD","MGTX","LU0048573561.USD","LU0868494617.USD","LU0210536198.USD","LU2237443465.HKD","IE00B19Z3581.USD","BK4533","LU1804176565.USD","LU2896262040.SGD","BK4550","GSX","LU1868836757.USD","IE00B19Z3B42.SGD","LU2471134796.USD","LU2471134523.USD","LU1144417596.USD","LU1868837300.USD","BK4552","IE0004091025.USD","LU0742534661.SGD","LU1868836914.USD","LU1894683264.USD","LU1668664300.SGD","LU2471134952.CNY","LU2237443549.SGD","LU0251142724.SGD","BK4516","LU2750360641.GBP","LU2237443382.USD","LU1868837136.USD","LU0868494708.USD","LU2237443622.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670411552","title":"MeiraGTx Files Initial Beneficial Ownership Statement for Director Alan Sebulsky","url":"https://stock-news.laohu8.com/highlight/detail?id=2670411552","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670411552?lang=en_us&edition=fundamental","pubTime":"2026-09-25 09:01","pubTimestamp":1790298085,"startTime":"0","endTime":"0","summary":"MeiraGTx files initial beneficial ownership statement for director Alan SebulskyMeiraGTx director Alan Sebulsky reported 34,500 ordinary shares held indirectly through Apothecary Capital LLC in an ini","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL277n54:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485273","title":"MeiraGTx appoints Sebulsky to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485273","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669485273?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:26","pubTimestamp":1790166396,"startTime":"0","endTime":"0","summary":"MeiraGTx (MGTX) announced the appointment of Alan Sebulsky to its Board of Directors. Sebulsky most recently served as Partner and Portfolio Manage...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/meiragtx-appoints-sebulsky-to-its-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/meiragtx-appoints-sebulsky-to-its-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669048394","title":"MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669048394","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669048394?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:00","pubTimestamp":1790164801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA5L8Z0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662296780","title":"Why MeiraGTx (MGTX) Is Up 7.7% After Swing to Q2 Profitability and New Leadership Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2662296780","media":"Simply Wall St.","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662296780?lang=en_us&edition=fundamental","pubTime":"2026-08-25 16:21","pubTimestamp":1787646091,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings plc reported past second-quarter 2026 results showing revenue rising to US$321.43 million and net income to US$160.72 million, alongside filing a US$12.96 million shelf registration and appointing seasoned industry leaders Penny Fleck and John Knighton to senior development and manufacturing roles earlier in 2026.\nThe sharp shift from prior-period losses to profitability, combined with leadership hires experienced in bringing complex therapies to market, materially reshapes...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mgtx/meiragtx-holdings/news/why-meiragtx-mgtx-is-up-77-after-swing-to-q2-profitability-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mgtx/meiragtx-holdings/news/why-meiragtx-mgtx-is-up-77-after-swing-to-q2-profitability-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660279413","title":"MeiraGTx CEO Alexandria Forbes Sells 62,000 Shares for $859,320","url":"https://stock-news.laohu8.com/highlight/detail?id=2660279413","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660279413?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:03","pubTimestamp":1787101434,"startTime":"0","endTime":"0","summary":"MeiraGTx CEO Alexandria Forbes sells 62,000 shares for $859,320MeiraGTx: President and CEO Alexandria Forbes sold 62,000 ordinary shares on Aug. 18, 2026.Sale priced at USD 13.86 per share.Direct hold","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL58M9pw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MeiraGTx CEO Alexandria Forbes Sells 62,000 Shares for $859,320","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659717188","title":"Profit Surge and New Leadership Might Change The Case For Investing In MeiraGTx Holdings (MGTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659717188","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659717188?lang=en_us&edition=fundamental","pubTime":"2026-08-16 09:23","pubTimestamp":1786843407,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings plc reported past second-quarter 2026 results showing revenue rising to US$321.43 million from US$3.69 million a year earlier, with net income improving to US$160.72 million from a US$38.8 million loss, alongside key leadership hires and a US$12.96 million shelf registration for 1,000,000 ordinary shares tied to an employee share plan.\nBy pairing a shift to profitability with senior executives experienced in taking complex therapies through approval and commercialization,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mgtx/meiragtx-holdings/news/profit-surge-and-new-leadership-might-change-the-case-for-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mgtx/meiragtx-holdings/news/profit-surge-and-new-leadership-might-change-the-case-for-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MGTX","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129647","title":"Emmaus Life Sciences Q2 Revenue Soars on Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129647","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129647?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:20","pubTimestamp":1786738826,"startTime":"0","endTime":"0","summary":"Emmaus Life Sciences Q2 revenue soars on licensing dealOverviewUS biopharmaceutical firm's Q2 revenue rose 124% yr/yr, driven by NIT license agreementCompany reduced operating expenses following sales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4539","EMMA","BK4007","BK4139","ETON","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659312657","title":"Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2659312657","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659312657?lang=en_us&edition=fundamental","pubTime":"2026-08-15 03:29","pubTimestamp":1786735753,"startTime":"0","endTime":"0","summary":"Inflammation drug developer HCW Biologics' Q2 net loss widensOverviewUS biopharma firm's Q2 revenue rose yr/yr, driven by licensing agreement completionCompany posted higher Q2 net loss compared to pr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0TM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4007","RANI","VTGN","BK4539","BK4139","HCWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659284921","title":"MeiraGTx Seen Nearing First Commercial Launches as Key Programs Advance, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659284921","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659284921?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:02","pubTimestamp":1786723359,"startTime":"0","endTime":"0","summary":"MeiraGTx  is moving closer to becoming a commercial-stage company, with two potential first-in-class treatments approaching approval, RBC Capital Markets said Thursday in a report.For X-linked retinitis pigmentosa, a rare inherited eye disease that causes progressive vision loss, MeiraGTx expects to file its biologics license application with the US Food and Drug Administration in 2026 and launch the treatment in 2027, the report said.For xerostomia, or chronic dry mouth, the Phase 2 study has finished enrollment and is on track to report 12-month results in Q2 2027, the report said. MeiraGTx expects to file with the FDA in mid-2027, with a possible approval late that year and a US launch in early 2028, RBC said.The company ended Q2 with $145 million in cash and expects to have funding into H2 2028, the report said.RBC raised its price target on MeiraGTx stock to $27 from $26 and maintained its outperform speculative risk rating.Price: 13.03, Change: +0.36, Percent Change: +2.84","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146826","title":"RBC Adjusts PT on MeiraGTx to $27 From $26, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146826","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146826?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:39","pubTimestamp":1786707571,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings (MGTX) has an average rating of buy and mean price target of $29.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145152","title":"Bank of America Securities Remains a Buy on Meiragtx Holdings (MGTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145152?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:15","pubTimestamp":1786706124,"startTime":"0","endTime":"0","summary":"In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Meiragtx Holdings, with a price target of $19...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-meiragtx-holdings-mgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-meiragtx-holdings-mgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0052756011.USD","LU0070302665.USD","LU0320765646.SGD","LU0640476718.USD","KBWB","LU1280957306.USD","BK4534","LU0980610538.SGD","LU0130103400.USD","LU0310800965.SGD","IE0001KFT4U8.USD","LU1989771016.USD","LU0130102774.USD","LU1496350502.SGD","XLF","LU0321505868.SGD","TFNS","BK4553","IYG","LU1791807156.HKD","LU0683600562.USD","FTXO","PGF","FNCL","IE00BLSP4452.SGD","LU1496350171.SGD","LU0314106906.USD","VFH","BK4588","LU0203345920.USD","LU0256863811.USD","LU1880398554.USD","LU2596442595.SGD","LU0868494617.USD","BAC","UYG","LU0306807586.USD","LU0477156797.USD","LU0306806265.USD","LU1804176565.USD","LU1366192091.USD","LU1035773651.USD","IYF","LU0648000940.SGD","MGTX","LU0098860793.USD","LU0787776722.HKD","LU0130517989.USD","LU1883839398.USD","LU0971096721.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659216654","title":"MeiraGTx Gains; Reports over $200 Mln in License Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659216654","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659216654?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:03","pubTimestamp":1786637026,"startTime":"0","endTime":"0","summary":"BUZZ-MeiraGTx gains; reports over $200 mln in license revenue** Shares of genetic medicine firm MeiraGTxMGTX.Orise 6% to $13.74** Company reports Q2 revenue of $321.43 million, including $204.6 million in license revenue. There was no license revenue a year earlier** License revenue relates to MeiraGTx's proprietary gene therapy delivery platform, which enables precise, small-volume brain infusions and has been licensed to Reogen Limited for the development of neurology-focused therapies, including Parkinson's disease** Including session's move, MGTX shares up 73% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL6N44A14H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659303168","title":"MeiraGTx Holdings PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659303168","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659303168?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:07","pubTimestamp":1786630064,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings SummaryMeiraGTx Holdings PLCMGTX.OQreported quarterly adjusted earnings of 86 cents per share for the quarter ended June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A1HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659574871","title":"Sector Update: Healthcare Stocks Advance Pre-Bell Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2659574871","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659574871?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:13","pubTimestamp":1786626787,"startTime":"0","endTime":"0","summary":"Healthcare stocks were advancing pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF  up 0.3% and the iShares Biotechnology ETF  0.6% higher.MeiraGTx  shares were up more than 7% after the company reported that it swung to a Q2 net income as revenue surged during the period.Cullinan Therapeutics , Taiho Oncology and Taiho Pharmaceutical said a phase 3 clinical trial evaluating the combination of their jointly developed drug zipalertinib and chemotherapy as a first-line treatment for adults with previously untreated, locally advanced or metastatic non-small cell lung cancer met its primary endpoint of progression-free survival. Shares of Cullinan Therapeutics were up more than 7% premarket.Ascendis Pharma  stock was up more than 1% after the company posted higher Q2 non-IFRS earnings and revenue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","XBI","HCSG","CGEM","LU0128526141.USD","ASND","XLV","LU0109394709.USD","BK4139","BK4581","LABU","MEDI","IBB","LU0029874061.USD","LU0889565916.HKD","MGTX","BK4137","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152820","title":"Shares of MeiraGTx Climb 7.1% Premarket After Q2 Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152820?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:33","pubTimestamp":1786624396,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4N44A112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MGTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.meiragtx.com","stockEarnings":[{"period":"1week","weight":-0.1231},{"period":"1month","weight":-0.1972},{"period":"3month","weight":-0.3489},{"period":"6month","weight":-0.1334},{"period":"1year","weight":-0.0082},{"period":"ytd","weight":0.0704}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.012037},{"month":2,"riseRate":0.5,"avgChangeRate":0.0333},{"month":3,"riseRate":0.25,"avgChangeRate":-0.052743},{"month":4,"riseRate":0.75,"avgChangeRate":-0.013966},{"month":5,"riseRate":0.625,"avgChangeRate":0.013491},{"month":6,"riseRate":0.5,"avgChangeRate":0.058638},{"month":7,"riseRate":0.555556,"avgChangeRate":0.008569},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.021408},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.025597},{"month":10,"riseRate":0.333333,"avgChangeRate":0.06271},{"month":11,"riseRate":0.555556,"avgChangeRate":0.034112},{"month":12,"riseRate":0.625,"avgChangeRate":0.053515}],"exchange":"NASDAQ","name":"Meiragtx Holdings Plc","nameEN":"Meiragtx Holdings Plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Meiragtx Holdings Plc(MGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Meiragtx Holdings Plc,MGTX,Meiragtx Holdings Plc股票,Meiragtx Holdings Plc股票老虎,Meiragtx Holdings Plc股票老虎国际,Meiragtx Holdings Plc行情,Meiragtx Holdings Plc股票行情,Meiragtx Holdings Plc股价,Meiragtx Holdings Plc股市,Meiragtx Holdings Plc股票价格,Meiragtx Holdings Plc股票交易,Meiragtx Holdings Plc股票购买,Meiragtx Holdings Plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Meiragtx Holdings Plc(MGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction